Presurgical weight loss, tumour traits & biomarkers.

[pjoshea13]

Interesting new study below.

A 7 week intervention with the aim of 1 kg (2.2 lbs) weight loss /week in "overweight and obese men with prostate cancer."

Mean weight decreased 4.7 kg (& even went down 2.2 kg in the control arm).

Testosterone increased by 55.1 ng/dL. Decreased 48.3  ng/ dL in controls.

Leptin was reduced, but no mention of adiponectin, which might have increased. They have an inverse relationship & adiponectin is protective.

"Follow-up Ki67 was significantly higher in WLI {weight loss intervention} vs control arms; median (interquartile range): 5.0 (2.5,10.0) vs 0.0 (0.0,2.5)"

"Antigen KI-67 is a nuclear protein that is associated with and may be necessary for cellular proliferation." [2]

Visceral fat can have a profound effect of PCa aggressiveness, & this short-term intervention provides proof-of-concept that weight loss can lower the proliferation index.

-Patrick

[1] ncbi.nlm.nih.gov/pubmed/288...

Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.303. [Epub ahead of print]

Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.

Demark-Wahnefried W1,2, Rais-Bahrami S2,3,4, Desmond RA2,5, Gordetsky JB3,6, Hunter GR7, Yang ES2,8, Azrad M1, Frugé AD1, Tsuruta Y1, Norian LA1,2, Segal R9, Grizzle WE2,6.

Author information

1

Department of Nutrition Sciences, Wallace Tumor Institute, University of Alabama at Birmingham, 1824 6th Avenue South, Suite 102, Birmingham, AL 35294, USA.

2

University of Alabama at Birmingham Comprehensive Cancer Center, Wallace Tumor Institute, 1824 6th Avenue South, Birmingham, AL 35294, USA.

3

Department of Urology, University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL 35233, USA.

4

Department of Radiology, 619 19th Street South, Birmingham, AL 35233, USA.

5

Division of Preventive Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, Birmingham, AL 35205, USA.

6

Division of Anatomic Pathology, Department of Pathology, University of Alabama at Birmingham, 619 19th Street South, Birmingham, AL 35233, USA.

7

Department of Human Studies, University of Alabama at Birmingham, 901 13th Street South, Birmingham, AL 35294, USA.

8

Department of Radiation Oncology, University of Alabama at Birmingham, 1700 6th Avenue South, Birmingham, AL 35233, USA.

9

Department of Medicine, University of Ottawa, 1053 Carling Avenue, Ottawa, ON K1Y 4E9, Canada.

Abstract

BACKGROUND:

Obesity is associated with aggressive prostate cancer. To explore whether weight loss favourably affects tumour biology and other outcomes, we undertook a presurgical trial among overweight and obese men with prostate cancer.

METHODS:

This single-blinded, two-arm randomised controlled trial explored outcomes of a presurgical weight loss intervention (WLI) that promoted ∼1 kg per week loss via caloric restriction and increased physical activity (PA). Forty overweight/obese men with clinically confirmed prostate cancer were randomised to the WLI presurgery or to a control arm; changes in weight, body composition, quality-of-life, circulating biomarkers, gene expression, and immunohistochemical markers in tumour and benign prostatic tissue were evaluated.

RESULTS:

The study period averaged 50 days. Mean (s.d.) change scores for the WLI vs control arms were as follows: weight: -4.7 (3.1) kg vs -2.2 (4.4) kg (P=0.0508); caloric intake: -500 (636) vs -159 (600) kcal per day (P=0.0034); PA: +0.9 (3.1) vs +1.7 (4.6) MET-hours per day (NS); vitality: +5.3 (7.l4) vs -1.8 (8.1) (P=0.0491); testosterone: +55.1 (86.0) vs -48.3 (203.7) ng dl-1 (P=0.0418); sex hormone-binding globulin: +14.0 (14.6) vs +1.8 (7.6) nmol l-1 (P=0.0023); and leptin: -2.16 (2.6) vs -0.03 (3.75) (P=0.0355). Follow-up Ki67 was significantly higher in WLI vs control arms; median (interquartile range): 5.0 (2.5,10.0) vs 0.0 (0.0,2.5) (P=0.0061) and several genes were upregulated, for example, CTSL, GSK3B, MED12, and LAMC2.

CONCLUSIONS:

Intentional weight loss shows mixed effects on circulating biomarkers, tumour gene expression, and proliferative markers. More study is needed before recommending weight loss, in particular rapid weight loss, among men with prostate cancer.British Journal of Cancer advance online publication: 7 September 2017; doi:10.1038/bjc.2017.303 bjcancer.com.

PMID: 28881355 DOI: 10.1038/bjc.2017.303

[2] en.wikipedia.org/wiki/Ki-67...